Table of Content

1. Executive Summary
1.1. Global Human Immunodeficiency Virus Therapeutics Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Drug Type Lifecycle Analysis
2.4. Global Human Immunodeficiency Virus Therapeutics Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global Human Immunodeficiency Virus Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Human Immunodeficiency Virus Therapeutics Market Outlook: Drug Type
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug Type, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
3.3.3.1. Branded Drugs
3.3.3.2. Generic Drugs
3.4. Market Attractiveness Analysis: Drug Type
3.5. Global Human Immunodeficiency Virus Therapeutics Market Outlook: Drug
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
3.5.3.1. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
3.5.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
3.5.3.3. Entry and Fusion Inhibitors
3.5.3.4. Others
3.6. Market Attractiveness Analysis: Drug
4. Global Human Immunodeficiency Virus Therapeutics Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Global Human Immunodeficiency Virus Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Drug Type
5.3.3. By Drug
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
5.5.1. Branded Drugs
5.5.2. Generic Drugs
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
5.6.1. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
5.6.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.6.3. Entry and Fusion Inhibitors
5.6.4. Others
5.7. Market Attractiveness Analysis
6. Europe Global Human Immunodeficiency Virus Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Drug Type
6.3.3. By Drug
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Türkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
6.5.1. Branded Drugs
6.5.2. Generic Drugs
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
6.6.1. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
6.6.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
6.6.3. Entry and Fusion Inhibitors
6.6.4. Others
6.7. Market Attractiveness Analysis
7. East Asia Global Human Immunodeficiency Virus Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Drug Type
7.3.3. By Drug
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
7.5.1. Branded Drugs
7.5.2. Generic Drugs
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
7.6.1. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
7.6.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
7.6.3. Entry and Fusion Inhibitors
7.6.4. Others
7.7. Market Attractiveness Analysis
8. South Asia & Oceania Global Human Immunodeficiency Virus Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Drug Type
8.3.3. By Drug
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
8.5.1. Branded Drugs
8.5.2. Generic Drugs
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
8.6.1. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
8.6.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
8.6.3. Entry and Fusion Inhibitors
8.6.4. Others
8.7. Market Attractiveness Analysis
9. Latin America Global Human Immunodeficiency Virus Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Drug Type
9.3.3. By Drug
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
9.5.1. Branded Drugs
9.5.2. Generic Drugs
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
9.6.1. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
9.6.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
9.6.3. Entry and Fusion Inhibitors
9.6.4. Others
9.7. Market Attractiveness Analysis
10. Middle East & Africa Global Human Immunodeficiency Virus Therapeutics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Drug
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
10.5.1. Branded Drugs
10.5.2. Generic Drugs
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
10.6.1. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
10.6.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
10.6.3. Entry and Fusion Inhibitors
10.6.4. Others
10.7. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Analog IC
11.2.3. Apparent Drug Type Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. AbbVie Inc.
11.3.1.1. Overview
11.3.1.2. Segments and Drug Type
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Boehringer Ingelheim International GmbH
11.3.2.1. Overview
11.3.2.2. Segments and Drug Type
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Bristol-Myers Squibb Company
11.3.3.1. Overview
11.3.3.2. Segments and Drug Type
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Cipla Inc.
11.3.4.1. Overview
11.3.4.2. Segments and Drug Type
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Genentech, Inc.
11.3.5.1. Overview
11.3.5.2. Segments and Drug Type
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Gilead Sciences, Inc.
11.3.6.1. Overview
11.3.6.2. Segments and Drug Type
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Merck & Co., Inc.
11.3.7.1. Overview
11.3.7.2. Segments and Drug Type
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. ViiV Healthcare
11.3.8.1. Overview
11.3.8.2. Segments and Drug Type
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations